Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aptinyx Advances NMDA Receptor Modulators To Ease Pain

Executive Summary

In the two years since Aptinyx was spun-out from predecessor Naurex, the US biotech has gone from being a preclinical company to one with two Phase II programs and a third to enter that stage in 3Q 2018. Company president and CEO, Norbert Riedel met up with Scrip at the 2018 Biotech Showcase and revealed how Aptinyx intends to spend the $70m it raised in a series B financing late last year.







Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts